ThinkPanmure Initiates Coverage on InterMune (ITMN) with an Accumulate
More News related to ITMN
- Morning Movers 11/17: ZOOM, SMTL, AGO, ABCW, XJT Higher; INOC, QUIK, PSUN, ERI, FTK, TBUS Lower
- InterMune (ITMN) Modifies On-Going Phase 2b Study of ITMN-191
- InterMune Announces Modification to On-Going Phase 2b Study of ITMN-191 in Patients with Chronic HCV Infection
- InterMune (ITMN) Reports Smaller-Than-Expected Loss; Guides In-line
- InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
More News related to New Coverage
- Cowen & Co Initiates Coverage on Delcath Systems (DCTH) with an Outperform
- WBB Securities Initiates Coverage on Electro-Optical Sciences (MELA) with a Sell
- JANCO Partners Initiates Coverage on Syniverse Technologies (SVR) with a Buy; Strong Competitive Position
- Citi Initiates Coverage on AGA Medical (AGAM) with a Buy
- Dahlman Rose Initiates Coverage on RailAmerica (RA) with a Hold
ThinkPanmure initiates coverage on InterMune (Nasdaq: ITMN) with an Accumulate. Price target $25.
InterMune, Inc. (InterMune) is a biotech company focused on developing and commercializing therapies in pulmonology and hepatology.
Related Categories
New CoverageStocks Mentioned
+0.34Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
